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Br J Clin Pharmacol. 2019;1–9.Aims: We aimed to assess and characterize sex differences in adverse drug reac-
tions (ADRs) reported to the national pharmacovigilance centre in the Netherlands
while considering differences in drug use.
Methods: ADRs spontaneously reported by healthcare professionals and patients
to the Netherlands pharmacovigilance centre Lareb were used. Drug–ADR combina-
tions reported at least 10 times between 2003–2016 for drugs used by ≥10,000 per-
sons in that period were included. Data about the number of drug users was obtained
from the National Health Care Institute. Sex‐specific ADRs, like gynaecological prob-
lems, were excluded. Sex differences in specific drug–ADR combinations were tested
using bivariate logistic regression analyses in which the number of drug users per sex
was taken into account.
Results: In total, 2483 drug–ADR combinations were analysed. Possibly relevant
sex differences were shown in 363 combinations (15%). Most of these drug–ADR
combinations were reported more often for women (322 combinations). Drugs with
the highest number of ADRs that were more often reported for women included thy-
roid hormones (32 combinations) and antidepressants (16 combinations for the cen-
trally acting sympathomimetics; 14 combinations for other antidepressants). Some
ADRs were predominantly reported for women across a range of drugs such as head-
ache and dizziness whereas other ADRs such as tendon ruptures and aggression were
reported more often for men.
Conclusions: Identified sex differences in reported ADRs often referred to women.
These differences may have various causes, including pharmacological and behav-
ioural causes, which need to be further assessed. The results may ultimately lead to
sex‐specific prescribing or monitoring recommendations.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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sexWhat is already known about this subject
• Women generally have a higher risk for adverse drug
reactions (ADRs) being reported than men.
• Information about possible sex differences is inconsistent
and incomplete at the specific drug and ADR level.
• More knowledge on sex differences in ADRs is needed to
tailor drug treatment and management in clinical practice.
What this study adds
• Drugs with a higher risk for ADRs being reported for
women included thyroid hormones, tumour necrosis
factor‐α inhibitors and several psychoanaleptics.
• A higher risk of specific ADRs being reported was shown
for both women and men for statins and selective
serotonin reuptake inhibitors.1 | INTRODUCTION
Adverse drug reactions (ADRs) are common in clinical practice. A study
using data from medical records showed that 12% of a randomly
selected sample of adults from the general public in Sweden had an
ADR in a 3‐month period of any of the drugs they used.1 Higher num-
bers of ADRs have been shown in studies using self‐reported data.
For instance, around 25% of patients in primary care in Boston reported
an ADR in a survey two weeks after receiving drug prescription by their
physician.2 There may be various explanations for differences in ADR
rates between studies including differences in data collection methods
and ADR definitions. In general, however, the numbers indicate a point
of concern since ADRs may be bothersome and may reduce treatment
adherence, efficacy, quality of life and increase healthcare costs.3-5
Many factors may influence the occurrence of ADRs6 including
sex. It has been shown that women have a 1.5–1.7 times higher risk
for ADRs than men.7 However, information is inconsistent and
incomplete at the specific drug and ADR level. For instance, 1 study
showed that men reported more ADRs to antineoplastic drugs than
women,8 whereas another study showed that women reported more
ADRs to antineoplastic drugs than men.9 Recently, a study assessed
sex differences in drug‐event combinations using the Food and Drug
Administration Adverse Event Reporting System.10 The study
showed significant differences between men and women in drug‐
event combination frequency distributions in 307 of the 668
assessed drugs but did not take sex differences in the number of
drug users into account. Previous studies showed that a higher pro-
portion of women use drugs than men, that women use different
drugs, and that women use more drugs than men.11-14
More knowledge on sex differences in ADRs is needed to tailor
drug treatment and management in clinical practice. The primary aim
of this study was to assess the extent of possibly relevant sex differ-
ences in drug–ADR combinations reported to a pharmacovigilance
centre, taking sex differences in the number of drug users into
account. The secondary aims of this study were to assess for which
drugs and for which ADRs sex differences were identified most often.2 | METHODS
2.1 | Study design and data sources
We conducted an explorative observational study to identify possibly
relevant sex differences in ADRs related to specific drugs. Data on
these drug–ADR combinations for individual patients that are
reported to the Netherlands pharmacovigilance centre Lareb from 1
January 2003 to 31 December 2016 were used. Healthcareprofessionals (HCPs) as well as patients are allowed to report ADRs
to Lareb,15,16 which is funded by the Ministry of Health, Welfare
and Sport, and the Dutch Medicines Evaluation Board. All ADR reports
related to drugs submitted to Lareb from patients, physicians and
pharmacists, concerning patients aged between 5 and 99 years old
were included (Figure 1).
Data from the Drug Information System of the National Health Care
Institute were used to retrieve the total number of women and men
using the specific drugs in the study period.17 These data are based
on reimbursement of drugs being used in an ambulatory setting, which
are available for women and men aged between 5 and 99 years old.2.2 | Outcome variable
The outcome variables used in this study were specific drug–ADR
combinations.
Drugs mentioned in the ADR report were classified according to
the Anatomical Therapeutic Chemical (ATC) classification system.18
In this system, drugs are divided on five different levels based on
the organ or system on which they act and their chemical, pharmaco-
logical, and therapeutic properties. For the specific drug assessment,
drugs on the chemical subgroup, the fourth ATC level was used.
Reported ADRs were classified according to the Medical Dictio-
nary for Regulatory Activities (MedDRA), version 20.0.19 The
MedDRA is a medical dictionary that contains five levels ranging from
very general (the System Organ Class level) to very specific terms (the
Lowest Level Term level). The fourth, preferred term (PT) level was
used for the ADR assessment which is the level most often used in
FIGURE 1 Flowchart of the number of drug–adverse drug reaction (ADR) combinations. 1 Anatomical therapeutic chemical (ATC) classification
system codes (number of combinations): B02BD (1); B06AA (1); J01GB (1); J01XB (1); L01CD (8); L01XA (13); L01XC (12); L04 AC (1); N02AJ (6);
N07BA (23); P01BB (16); R01AA (2); S01JA (1). 2 ATC codes (number of combinations): B03AC (16); G02BA (37); G02BB (10); G03AA (46);
G03 AC (10); G03 AD (1); G03CA (10); G03HB (18); L02BG (8). 3 ATC codes (number of combinations): G04BE (2); G04CB (2) 4 medical dictionary
for regulatory activities (MedDRA) preferred level terms (number of combinations): ejaculation disorder (2); ejaculation failure (1); erectile
dysfunction (15); gynaecomastia (7); priapism (1) 5 MedDRA terms (number of combinations): amenorrhoea (1); female orgasmic disorder (1);
menopausal symptoms (1); menstrual disorder (1); menstruation irregular (1); metrorrhagia (1); vaginal haemorrhage (1); vulvovaginal burning
sensation (1); vulvovaginal candidiasis (1); vulvovaginal pruritus (1)
DE VRIES ET AL. 3safety reporting for analysis.20 The use of the PT level implies that a
report containing several ADRs on the lowest level of detail but within
the same PT were counted once.2.3 | Determinant
The determinant used in this study was the sex (i.e. women vs men) of
the patients for which an ADR was reported. Reports indicating that
sex was unknown were excluded.2.4 | Analyses
Descriptive statistics were used to analyse the reports. Sex differences
in specific drug–ADR combinations were assessed for combinations
mentioned in at least 10 reports (Figure 1). This number was arbitrarily
chosen as being appropriate for detection of all possibly relevant sex
differences in drug–ADR combinations. Duplicate reports (i.e. those
reported by both patients and HCPs) were counted only once.
For both women and men, the number of users was calculated per
drug resulting in the total number of users in the study period. Drug–
4 DE VRIES ET AL.ADR combinations for which the total number of men or the total
number of women using the drug in the population over the 14‐year
study period was <10 000 were excluded. Sex‐specific ADRs as
labelled in the Gender Adverse Event Term Lists of the MedDRA21
were also excluded (Figure 1).
Sex differences in the remaining specific drug–ADR combinations
were tested using bivariate logistic regression analyses in which the
number of users of the specific drug in the study period was taken into
account. In these analyses, our total population consisted of all users
of the specific drug in the study period with the number of individuals
experiencing the ADR being the number of reports received in the
study period. Odds ratios and 95% confidence intervals (CIs) were cal-
culated for each specific drug–ADR combination, and associations
with P‐values <.05 are reported. Since the aim was to identify all pos-
sibly relevant sex differences, the results were not adjusted for multi-
ple testing. A sensitivity analysis was conducted to assess the
agreement of the findings between the patient and HCP reports. For
this, the patient and HCP reports were analysed separately. All analy-
ses were conducted using Stata version 13 (Stata Corp., College Sta-
tion, TX, USA) and Microsoft Excel 2010 was used for a graphical
presentation of the results.3 | RESULTS
In the study period, there were 80 118 ADR reports in which 268 584
drug–ADR combinations were reported. These concerned 50 293 dis-
tinct drug–ADR combinations (Figure 1). After exclusion of reports,
there were 42 855 ADR reports who fulfilled the inclusion criteria.
Two thirds of these reports (67%) concerned women. The mean ±
standard deviation age in the reports concerning women was 51 ±
18 years and for men 56 ± 18 years. In total, 80 049 drug–ADR com-
binations were reported, which concerned 2765 distinct drug–ADR
combinations (Figure 1).3.1 | Sex differences in specific drug–ADR
combinations
Of the 2765 distinct drug–ADR combinations, 246 combinations were
excluded because the number of drug users in the study period was
<10 000. Another 36 combinations were excluded because of a sex‐
specific ADR (Figure 1). Among the remaining 2483 combinations
there were 103 drug–ADR combinations (4%) reported for 1 sex only.
A possibly relevant sex difference was shown in 363 combinations
(15%), which concerned 74 different drugs and 124 different ADRs.
In most of these cases (89%), women had a higher odds ratio for a spe-
cific drug–ADR combination than men (322 vs 41 combinations). The
results of all 2483 combinations are presented in Data S1.
For some drugs and ADRs, a multitude of sex differences were
shown. Most common drugs with a multitude of ADRs for which
women had higher odds were: thyroid hormones (ATC group H03AA;
32 combinations); centrally acting sympathomimetics (N06BA; 16 com-
binations); other antidepressants (N06AX; 14 combinations); andtumour necrosis factor‐α inhibitors (L04AB; 14 combinations). The
most common ADRs with a multitude of differences with higher odds
for women were: nausea (32 combinations); alopecia (28 combina-
tions); headache (20 combinations); dizziness (18 combinations); and
palpitations (18 combinations). Higher odds for men were particularly
shown in combinations with the following ADRs: aggression; death;
pyrexia; sexual dysfunction; tendon rupture; and tinnitus (all in 2
combinations).
Drugs for which a higher odds ratio was shown for a multitude of
ADRs in both men and women, were β‐hydroxy β‐methylglutaryl
(HMG)‐CoA reductase inhibitors (C10AA; 20 combinations with
higher odds for women and 5 combinations with higher odds for
men), and selective serotonin reuptake inhibitors (N06AB; 13 combi-
nations with higher odds for women and 10 combinations with higher
odds for men). The type of ADRs for HMG CoA reductase inhibitors
(range for women: OR 7.23, 95% CI 1.62–32.29 for swollen tongue
to OR 1.54, 95% CI 1.05–2.27 for palpitations; range for men: OR
0.05, 95% CI 0.01–0.34 for libido decreased to OR 0.44, 95% CI
0.19–0.98 for pancreatitis; Figure 2) and selective serotonin reuptake
inhibitors (range for women: OR 6.19, 95% CI 1.91–20.06 for
haematoma to OR 1.66, 95% CI 1.12–2.47 for nausea; range for
men: OR 0.21, 95% CI 0.06–0.83 for micturition disorder to OR
0.62, 95% CI 0.45–0.85 for therapeutic response unexpected;
Figure 3) with higher odds for men were different than the ADRs with
higher odds for women.
Overall, the drug–ADR combinations with possibly relevant sex
differences were shown in various drug classes (Figure 4) and ADR
classes (Figure 5). For the sensitivity analysis, 537 drug–ADR combina-
tions were tested using both the patient and HCP reports. Agreement
in significance was shown in 397 drug–ADR combinations (74%;
Figure S2).4 | DISCUSSION
We found that 15% of approximately 2500 drug–ADR combinations
reported to the pharmacovigilance centre showed a possibly relevant
difference in occurrence of ADRs between women and men after tak-
ing sex differences in drug use into account. In 89% of these cases, the
risk was higher for women than for men. Drugs with a multitude of
ADRs showing a higher risk for women included thyroid hormones,
tumour necrosis factor‐α inhibitors and several psychoanaleptics. A
higher risk of specific ADRs for both women and men was shown
for HMG CoA reductase inhibitors (women: e.g. alopecia and head-
ache; men: e.g. decreased libido and tendon rupture) and selective
serotonin reuptake inhibitors (women: e.g. dizziness and nausea; men:
e.g. aggression and sexual dysfunction). In general, several specific
ADRs were more often reported for either women or men across a
range of drugs, including nausea, alopecia and headache for women,
and aggression, sexual dysfunction and tendon rupture for men.
Our study confirms findings from previous studies demon-
strating that women have a higher risk for reporting ADRs than men
(e.g.7,8,12,22-26). It adds to this knowledge by presenting an overview
FIGURE 2 Odds ratios with 95% confidence intervals of adverse drug reactions with higher odds for women (left side) or for men (right side) of
β‐hydroxy β‐methylglutaryl‐CoA reductase inhibitors
FIGURE 3 Odds ratios with 95% confidence intervals of adverse drug reactions with higher odds for women for (left side) or for men (right side)
of selective serotonin reuptake inhibitors
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shows that men may have a higher risk for other specific drug–ADR
combinations. Compared to other studies, our study assessed drugs
and ADRs at a specific level and took sex differences in drug
prescribing into account. Previous studies analysing ADRs at system
organ class level showed for instance a higher risk for women in
cardiac disorders26 and a higher risk for men in renal and urinary
disorders.10 According to the current study, the higher risk for
women seems to apply particularly to palpitations and the higher
risk for men to haematuria, micturition disorder and pollakiuria
(Figure S3).
Observed differences in the type and number of reported ADRs
can be caused by sex‐ or gender‐related factors. Sex‐related factors
refer to biological differences between women and men, whereas
gender‐related factors refer to psychosocial, behavioural or cultural
differences.27 Sex‐related differences that are relevant for thepharmacokinetic and pharmacodynamic behaviour of drugs include
differences in physiology, genetic expression, immunological pro-
cesses, and type and function of various hormones.28-33 For instance,
women generally have a lower body weight. Therefore, one would
expect more so‐called type A ADRs in women. Type A reactions are
dose dependent, occur frequently, have a low mortality, and can be
explained based on the pharmacological properties of the drug.34 In
clinical practice, some sex‐specific dose adjustments are recom-
mended or used. For example, in the case of zolpidem, where women
have a lower clearance than men, lower doses are recommended and
prescribed for women.35,36 In the current study, several of the com-
mon type A ADRs, such as nausea, headache and dizziness, were
indeed predominantly present in women. However, no significant dif-
ferences in reported ADRs for drugs with known differences in phar-
macological properties, such as benzodiazepines or verapamil were
observed.37,38 For some drug classes such as β‐blocking agents,
FIGURE 4 Overview of number of combinations for drug classes with ≥20 combinations ordered by anatomical therapeutic chemical (ATC)
codes. The full list is presented in Figure S1
6 DE VRIES ET AL.specific ADRs (e.g. palpitations) occurred more in women whereas
other ADRs (e.g. coldness) occurred more in men.
ADRs are classified as type B reactions if these cannot be
explained by pharmacological properties of the drug, which occur less
frequently and are often more serious in nature. In the current study,
some of the ADRs that were more present in men, may be type B
reactions, such as aggression and tendon ruptures. However, these
differences could also be explained by differences in background inci-
dence of the phenomenon as tendon ruptures and aggression occur
more frequently in men than in women without using drugs.
Besides sex‐related factors, differences in social roles, lifestyle fac-
tors, communication styles, health information‐seeking behaviour, and
medication prescribing and adherence could also lead to gender‐
specific differences in the occurrence, perception and reporting of
ADRs. Some ADRs are more likely to be perceived or reported by
either women or men, since the burden may depend on gender spe-
cific self‐image. An example is the occurrence of hair loss, which ismore common in aging men than in aging women.39-41 Therefore, alo-
pecia that occurs or is perceived as an ADR is likely to be considered
as more disturbing in women than in men, which may explain more
reports in women in the current study.
Reporting ADRs requires that the patient assigns signs or symp-
toms to a drug. Women and men may perceive these differently.42
Women appear to search more actively for health information than
men.43,44 Patients can either report by themselves or contact their
healthcare professional who can decide to report. To our knowledge,
possible sex differences in respect to ADR reporting behaviour have
not been widely studied. It is known that there is underreporting of
ADRs in spontaneous reporting45 but it seems that sex of the patient
is not a factor for healthcare professionals in decision making whether
or not to report an ADR to the pharmacovigilance centre.46,47 More-
over, there seem to be no differences in reasons for and opinions
about ADR reporting between female and male patients who report
to a pharmacovigilance centre.48 Our study contained reports of both
FIGURE 5 Overview of number of combinations per adverse drug reaction with ≥20 combinations ordered by system organ class. The full list is
presented in Figure S3
DE VRIES ET AL. 7patients and HCPs. Separate analyses of the patient and HCP reports
showed similar sex differences in drug–ADR combinations (Figure S2),
suggesting that the observed differences are not due to sex differ-
ences in spontaneous reporting behaviour.
The occurrence of ADRs is clearly related to drug exposure. In the
analyses, the number of drug users was taken into account, but indi-
vidual drug exposure is dependent on medication prescribing and
adherence behaviour. There can be differences in the dose or duration
of drugs prescribed to women as compared to men. For example,
women are more often prescribed a low‐dose of HMG CoA reductase
inhibitors at treatment initiation than men who are more often pre-
scribed the standard dose.49 Also, women may receive more co‐
prescriptions, which could lead to a higher risk for ADRs.50 Previous
studies are inconsistent about sex differences in adherence levels.51
To summarize, it is likely that both sex‐related and sex‐related fac-
tors may underlie the observed differences between women and menin drug–ADR combinations as reported to the pharmacovigilance cen-
tre. The distinction between sex‐ and sex‐related factors, however, is
not straightforward since they are correlated and can influence each
other.52-54 Further in‐depth studies are needed for the specific
drug–ADR combinations with possibly relevant sex differences to
assess the individual contribution of potential factors.
A strength of this study is the assessment of differences between
women and men for all reported drug–ADR combinations while taking
differences in the number of drug users into account. Trained asses-
sors at the pharmacovigilance centre classified the ADRs using the
MedDRA terms system. ADRs were analysed at the PT level to reduce
possible inconsistent coding at the lowest level.
There are also some limitations that need to be acknowledged. We
combined all ADR reports and the number of drug users per sex in the
study period. Due to this aggregated level, we were not able to adjust
for potential confounding factors at individual level, such as age.
8 DE VRIES ET AL.Therefore, we cannot make inferences at individual patient level. The
number of drug users was based on data of reimbursed drugs pre-
scribed in an ambulatory setting. This implies that drugs prescribed
in another setting or used over‐the‐counter were not included. Fur-
thermore, we analysed drugs at the chemical subgroup level of the
ATC system but not all drugs that belong to a specific chemical sub-
group can be considered as pharmacotherapeutically equivalent.
Therefore, some relevant sex differences in ADRs may have been
missed at the lowest level of the ATC system. However, a study
assessing the heterogeneity of drugs within ATC classes showed that
the mechanism of action and physiological effects of drugs in most
classes were fairly homogeneous.55 Another limitation is the differ-
ence in number of cases for drug–ADR combinations (ranging from
10 to 1992), yielding differences in power. Moreover, some combina-
tions were reported for either women or men only, but this mainly
occurred for drugs with a higher number of users in women or men,
respectively. Finally, the study was conducted using spontaneously
reported ADRs to the pharmacovigilance centre in the Netherlands.
Since cultural differences between men and women may influence
the spontaneous reporting of ADRs, it is unknown to what extent
the results are generalizable to other countries.
In conclusion, this study showed possibly relevant differences
between women and men in 15% of the assessed drug–ADR combina-
tions spontaneously reported to a pharmacovigilance centre. Both
sex‐ and gender‐related factors may play a role in explaining the
observed differences in ADRs.
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